Hormone Restoration Therapies with Natural (Bioidentical) Hormones
There are many different kinds of physical hormone therapy (bio-H.R.T.) That function in various ways.
Diagnosis of Real Causes & Treatments of Menopause
- Gradual restoration of cellular function
- Personalized therapeutic protocols, without chemical residues and excipients
- Treating the real causes
- Therapeutic formulas that work alone or in combination with any other medication
- Adopting a Molecular / Therapeutic Nutrition Plan
Natural Hormone Restoration Therapies
- Disappearance of menopausal symptoms (headache, hot flashes, sweating, insomnia, irritability, depression, hair loss)
- No side effects
- Prevention of Osteoporosis
- Prevention of Cardiovascular Diseases
- No chemicals
- Weight management
- Hormones Identical to human, with the exact same composition and structure
What exactly are “Natural (Bioidentical) Hormones”?
Natural hormones are processed in the laboratory and have the same molecular structure as the hormones produced and used by our body. In contrast, synthetic hormones are deliberately different.
Pharmaceutical companies cannot patent a physical structure, as is the case with synthetic hormones.
Natural hormones act in our body, just like the hormones we produce.
Micro-modified natural estrogen and progesterone is a series of products, constructed in specialized pharmacies. It is available in various forms, such as pills, drops, patches, creams, gels as well as in various intravaginal preparations.
Natural progesterone can be administrated in the form of a capsule or a vaginal gel, a cream, drops or even suppositories. There is also natural testosterone in the form of drops, cream, gel or tablets.
What are the advantages of natural hormones over theis synthetic counterpants?
The great faze of natural (bioidentical) hormones is due to the fact that our body can metabolize them, as it is designed to do with its own, without zero side effects.
Synthetic hormones on the other hand are quite potent with side effects. They are inflammatory (increasing the inflammatory value CRP) as opposed to the natural ones, which are anti-inflammatory and therefore anti-aging.
Natural (bioidentical) hormones bind to our hormone receptors, just like the key fits to its lock, thus giving an immediate effect unlike conventional hormone replacement therapy, where synthetic hormones are “poured upon” the hormone receptors, but also bind on other steroid receptor sites, resulting in a host of side effects.
Another great advantage of natural – bioidentical hormones is that their levels are measurable, so they can be monitored more accurately, with blood tests and even more accurately, when the levels are tested through saliva sample.
There is no better proof of safety for the natural hormones than pregnancy. The hormonal process in pregnancy is extreme. Estrogen levels increase tenfold, progesterone 100%, growth hormone and testosterone increase by 20%.
And of course estriol, the hormone that increases during pregnancy and is a key ingredient in natural estrogen preparation, has been shown to be extremely safe for breast cancer.
Hormone dysfunction in patients with Chronic and Autoimmune Diseases is almost always observed. After relevant examinations that include Bio 4h Hormonal Profile, the special needs of each individual are detected.
The tests are affordable and the results are ready in two to three days.
The treatment is selected throughout various Bioidentical Hormone Protocols and then individualized based on testing and clinical assesment.
Treatment with natural hormones, depending on the disease, the extent of the damage and individual findings, can take from three months to a year for full clinical restoration.
Patients do not change their daily routine, while they gradually experience an improvement in their overall health and vitality.
These clinical therapies have been used systematically since 1993, starting in the United States.
These treatments have been systematically used have been used systematically in clinical practice since 1993, starting in the United States.
Action of Physical – Biomimetic Hormones
Estrogen (all three forms, estrone, estriol)
- Reduces LDL and prevents its oxidation.
- Increases HDL that has a protective effect
- Reduces Lp (a)
- Reduces atherosclerosis
- Reduces the risk of colon cancer
- Acts as a natural calcium inhibitor to keep the arteries open.
- Helps in the formation of neurotransmitters, such as serotonin, which reduces depression, anxiety, irritability, and sensitivity to pain.
- Reduces wrinkles
- Enhances Mg absorption
- Improves vessel elasticity
- Helps to maintain memory and concentration
- Maintains bone density and collagen
- Protects against macular degeneration, cataracts and hearing loss
- Increases the metabolic rate, resulting in proper weight maintenance
- Reduces Homocysteine
- Reduces inflammatory responses and free radicals
- Reduces the risk of cardiovascular disease by 50%
- Balances estrogen levels
- Increases the action of thyroid hormones
- Has a diuretic effect
- Has antidepressant and sedative action
- Has anti-inflammatory properties
- Reduces blood pressure
- Improves sleep
- Helps to maintain oxygen in cells
- Helps morning awakening and vigilance
- Increases metabolic rate
- Reduces cholesterol and increases HDL levels
- Offers a protective effect against breast cancer and fibrocystic breast disease
- Offers a protective effect against endometrial cancer, polyps and hyperplasia
- Offers a protective effect against ovarian cysts and ovarian cancer
- Increases the action of the immune system
- Prevents migraines
- Enhance smooth muscle fibers relaxation the smooth muscle fibers
- Stimulates the bone production
- Reduces the low blood sugar symptoms and the need for sweets and carbohydrates
- Reduces the breast pain (mastodynia) and the symptoms of premenstrual syndrome
- Reduces bone damage
- Reduces body fat
- Increases norepinephrine in the brain
- Helps to maintain memory
- Increases strength and muscle mass
- Increases muscle tone
- Increases self-confidence and well-being
- Improves the balance and hand-edge coordination
- Enhances the production of the nitric oxide (NO) production resulting in dilated blood vessels
- Reduces allergic reactions
- Reduces cholesterol blood levels
- Reduces deposition of fatty acids
- Reduces triglycerides
- Increases muscle mass
- Increases brain function
- Prevents blood clots
- Enhances weight-loss
- Reduces insulin resistance
- Has antistress properties
- Strengthens immune system
- Improves sleep patternts
- Increases energy and vitality
- Can boost your mood
- Increases stress resistance
- Facilitates GABA (neurotransmitter) to enter the brain
- Reduces the pain and inflammation
- Enhances memory
- Strengthens the immune system
Adams, Μ. R., et al. “Medroxyprogesterone acetate antagonizes inhibitory effects of conjugatedequine estrogens οτι coronary artery atherosclerosis.” Arterioscler Thromb Vαsc ΒίοΙ, January 1997, 17 (1): 217-21.
Antonijevic, Irina, et al. “Modulation of the sleep electroencephalogram by estrogen replacement ίτι postmenopausal women.” Americαn Journαl ΟΙ Obstetrics αnd Gynecology, February 2000: 277.
Aparasu, R. R. “Visits to office-based physicians ίη the United States for medication-related morbidity.” Journαl ΟΙ the Americαn Phαrm Asso, May- June 1999,39 (3): 332-7.
Araneo, Β., et al. “DHEAS as an effectiνe νaccine adjuνant ίη elderly humans.” Annαls ΟΙ the New York Acαdemy ΟΙ Sciences, 1995, 774: 232-48.
Arlt, W, et al. “Dehydroepiandrosterone replacement ίτι women wίth adrenal insufficiency.” New Englαnd Joumαl ΟΙ Medicine, September 30, 1999,341 (14): 1013-20.
Badwe, R. Α., et al. “Timing of surgery during menstrual cycle and surviνal of premenopausal women wίth operable breast cancer.” Lαncet, 1991, 337: 1261-4.
Bailar, ]ohn C., and Gornik, Heather. “Cancer undefeated.” New Englαnd Journαl oJMedicine, May 29,1997,336 (22): 1569-74.
Barrett-Connor, Ε., et al. “The epidemiology ofDHEAS and cardioνascular disease.” Annαls oJ the Νενν York Acαdemy oJ Sciences, 1995, 774: 259-70.
Bartsch, C., and Bartsch, Η. “Melatonin ίn cancer patients and ίn tumor- bearing animals.” Advances ίπ Exper Med ΒίοΙ, 1999,467: 247-64.
Batt, Sharon, and Gross, Liza. “Cancer, Inc.” Sierrα Mαgαzine, September/Oc- tober 1999: 36.
Baulieu, Ε. Ε., et al. “Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue.” Proceedings oJ the Nαtional Acαdemy oJ Sciences USA, Αρτί] 11,2000,97 (8): 4279-84.
Baum, Α. L. “Selectiνe serotonin-reuptake inhibitors ίn pregnancy and lactation.” Hαrναrd Review oJ Psychiαtry, September 1996,4 (3): 117-25.
Bilimoria, Μ. Μ., et al. ”Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics.” Annαls oJ Surgicαl On cology, 1999,6: 200-7
Bluming, Α. Ζ., et al. ”Hormone replacement therapy ίn women with preνiously treated Ρήmary breast cancer.” Proceedings oJ the Annuαl Meeting oJ the Americαn Society oJ αίπίcαI Oncology, 1994, Abstract A137.
Bonnier, Ρ, et al. “Clinical and biologic prognostic factors ίn breast cancer diagnosed during postmenopausal hormone replacement therapy” Ob- stetrics and Gynecology, 1995,85: 11.
Bradlow, Η. Ι., et al. ”Indole-3-carbinol: Α noνel approach to breast cancer preνention.” Appearing ίn “Cancer Preνention. From the Laboratory to the Clinic: Implications of Genetic, Molecular and Preνentiνe Research,” Annals oJ the New York Acαdemy oJ Sciences, September 1995, 768: 180-200. And also: “Multifunctional aspects of the action of indole-3-
carbinol as an antitumor agent,” Annαls oJ the Νενν York Acαdemy oJ Sciences, 1999,889: 204-13.
Brody, ]ane Ε. “Restoring ebbing hormones may slow aging.” Νενν York Times, ]uly 18, 1995, Ο.
Coulan, C. Β., et al. “Chronic anovulation may increase postmenopau.sal. breast cancer ήsk.” ]oumal oJ the Ameιican Medical Association, 1983 , 249: 445-6.
Cowan, Ι. D., et al. “Breast cancer incidence ίη women with a history of pro- gesterone deficiency” American ]ournal oJ Epidemiology, August 19 81 114 (2): 209-17.
Cromer, Β. Α. ‘Έffects of hormonal contraceptives οτι bone mineral density. DrugSaJety, March 1999,20 (3): 213-22.
Cundy, Τ, et al. “Spinal bone density ίτι women using depot medroxypro gesterone contraception.” Obstetrics and Gynecology, October 1998, 92 (4) pt 1): 569-73.
Davelaer. ‘Έχοgeηοus estrogen (Ε2) subcutaneous protective?” Tijdschr Ge- neeskd, 1991, 135 (14): 613-15.
Dew, J., et al. ‘Ά cohort study of hormonal replacement therapy given ιο women previously treated for breast cancer.” Climacteιic, 1998, 1:137-42.
DiSaia, Ρ. J., et al. ”Hormone replacement ίη breast cancer.” Lancet, 1993 342: 1232.
Dollins, Α. Β., et al. ‘Έffect of inducing nocturnal serum melatonin concen- trations ίτι daytime οτι sleep, mood, body temperature, and perfor- mance.” Proceedings oJ the National Academy oJ 5ciences, 1994, 91: 1824-28.
Eden, J. Α., et al. ‘Ά case-controlled study of combined continuous estrogen- progestin replacement therapy amongst women with a personal history ofbreast cancer.” Menopause, 1995,2: 67-72.
Ewertz, Μ. ”Influences of noncontraceptive exogenous sex hormones οτι breast cancer risk ίτι Denmark.” Cited by Gambrell, presentation paper.
Feldman, D. Ι., et al. “Cytoplasmic glucocorticoid binding proteins ίn bone cells.” Endocrinology, 1975,96: 29-36.
Fishman, J., et al. ”Increased estrogen-16-alpha-hydroxylase activity in women with breast and endometrial cancer.” ]ournal oJ Steroidal Biochem- istry, ΑρτΗ1984, 20 (4Β): 1077-81.
Fitzpatrick, Lorraine, and Good, Andrew. “Micronized progesterone: cliniah indications and οοηιρετίεοα with current treatments.”‘Fertility and Steril- ity, September 1999, 72 (3): 389-97.
Folkard, 5., Arendt, ]., et al. “Can melatonin improve shift workers’ toler- ance of the night shift? Ξοπιε preliminary findings.” Chronobiology Int., 1993, 10: 315-20.
Food and Drug Administration. “Tampons and asbestos, dioxin &: toxic shock syndrome.” Report from the Center for Deνices and Radiological Health,]uly 23,1999.
Formby, Β., and Wiley, Τ. 5. “Progesterone inhibits growth and induces apoptosis ίτι breast cancer cells: inverse effects οτι Bcl-2 and ρ53.” Annals ΟΙ Clinical Laboratory Sci, November-December 1998, 28 (6): 360-9.
Fortunati, Ν. “5ex hormone-binding globulin: Νοι οηlΥ a transport pro- tein.” Journal ΟΙ Endocrίne Investigation, March 1999,22 (3): 223-34.
Franceschi, 5., et al. “The role of energy and fat ίη cancers of the breast and colon-rectum ίη a southern European population.” Annals ΟΙ Oncology, 1999, 10 5upplement 6: 61-3.
Gaby, Alan R. Preventing and Reversing Osteoporosis. Rocklin, Cal.: Prima Publications, 1995.
Gajdos, Csaba, et al. “Breastcancer diagnosed duήηg hormone replacement therapy.” Obstetrίcs and Gynecology, Αρή12000, 95 (4): 513-18.
Gambrell, R. Don, et al. “Decreased incidence of breast cancer ίη post- menopausal estrogen-progestogen users.” Obstetrίcs-Gynecology, October 1983,62 (4):435-43.
Gambrell, R. Don, ]τ. ”Hormone replacement therapy and breast cancer.”
Maturίtas, August 1987,9 (2): 123-33.
Hargrove, ]oel Τ., et al. “Αοεοτριίοτι of oral progesterone is influenced by ve- hicle and particle size.” Amerίcan Joumal ΟΙ Obstetrίcs and Gynecology, 1989,161 (4): 948-51.
Helzlsouer, Kathy, et al. “Relationship of prediagnostic serum levels of dehy- droepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer.” Cancer Research, ]anuary